Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine

Xenon Pharmaceuticals Inc's XENE collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc NBIX achieved a regulatory milestone, triggering a payment of $15.0 million to Xenon

  • The FDA accepted Neurocrine's protocol amendment that expands the study population to include subjects between 2 and 11 years in the ongoing Phase 2 study of NBI-921352 in pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
  • Under the agreement, Xenon will receive an aggregate of $15.0 million from Neurocrine in the form of a $6.75 million payment in cash and an $8.25 million equity investment at a Xenon per share price of $31.855.
  • Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. 
  • Price Action: XENE shares are down 2.04% at $29.79 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!